Autologous chondrocyte processed products(Cyberdyne)

N/A

Report date: 2024/09/25 11:35:23

Base Information

Drug NameAutologous chondrocyte processed products(Cyberdyne)
Drug Alias NameCyborg™IK-01
ClassificationCell and gene therapy > Cell therapy > Donor > AutologousCell and gene therapy > Cell therapy > Somatic cell > Cartilage cell therapy
Mechanisms of ActionCell replacements
TargetsNot applicable
Therapy Area/IndicationsFractures, BoneOsteoarthritis, Knee
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryJapan
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaN/A
Originator CompaniesCyberdyne IncHirosaki University
China Registration ClassN/A

Develop Information

Active CompaniesCyberdyne Inc
Inactive CompaniesN/A
Active IndicationsFractures, BoneOsteoarthritis, Knee
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A